Crispr Therapeutics shares tumble after significant earnings miss
Prothena Corp (NASDAQ:PRTA), currently trading at $5.08 and identified as undervalued by InvestingPro analysis, received positive news as its partner Roche decided to advance prasinezumab into Phase 3 development for early-stage Parkinson’s disease. The decision comes despite Prothena’s recent setback with birtamimab, which failed to meet its primary endpoint. The company, with a market capitalization of $273 million, has seen its shares decline 75% over the past year.
Roche based its decision on encouraging Phase 2b PADOVA results and longer-term follow-up data suggesting clinical benefit when prasinezumab is used in addition to symptomatic treatment. A pre-specified analysis showed the drug’s effect was more pronounced in patients treated with levodopa, with a hazard ratio of 0.79, despite missing the primary endpoint of time to confirmed motor progression in the broader population. According to InvestingPro data, Prothena maintains a strong financial position with a current ratio of 9.0 and minimal debt-to-equity of 0.02.
Longer-term follow-up data revealed trends toward reduced motor progression at two years, showing 30-40% relative reduction versus placebo. These results supported Roche’s decision to move forward with the late-stage development program.
Oppenheimer maintained its Perform rating on Prothena stock following the announcement. The firm noted that while this positive development may not carry immediate financial implications for Prothena, it represents potential long-term value.
The advancement of prasinezumab to Phase 3 marks an important milestone for Prothena’s neuroscience pipeline, particularly following the disappointment with birtamimab. The drug aims to address the significant unmet need in Parkinson’s disease treatment. Analysts maintain optimistic price targets, with InvestingPro showing targets ranging from $4 to $81. Get access to the comprehensive Pro Research Report for deeper insights into Prothena’s pipeline potential and financial outlook, along with over 1,400 other detailed company analyses.
In other recent news, Prothena Corporation announced the advancement of prasinezumab into Phase III trials for early-stage Parkinson’s disease, following promising data from the Phase IIb PADOVA study. This development is part of a collaboration with Roche, with potential milestone payments and royalties for Prothena. Meanwhile, BofA Securities downgraded Prothena’s stock from Neutral to Underperform, citing the failure of its lead drug, birtamimab, in a crucial Phase III trial. The firm’s price target for Prothena was significantly reduced from $22 to $4. Piper Sandler also adjusted Prothena’s outlook, lowering the price target from $110 to $81, but maintained an Overweight rating due to the potential of PRX012, an Alzheimer’s disease treatment.
Cantor Fitzgerald downgraded Prothena’s stock to Neutral, expressing skepticism about the company’s ability to unlock value as a stand-alone entity. The firm noted Prothena’s collaborations with Roche, Novo Nordisk (NYSE:NVO), and Bristol Myers (NYSE:BMY) Squibb in various clinical trials. H.C. Wainwright revised Prothena’s price target to $14 from $30, maintaining a Buy rating. The revision followed the discontinuation of the AFFIRM-AL trial, prompting Prothena to focus on its Alzheimer’s pipeline, particularly PRX012. Analysts at H.C. Wainwright emphasized the potential of PRX012 in the Alzheimer’s treatment landscape, with upcoming data expected to demonstrate its competitive edge. These developments highlight the challenges and opportunities facing Prothena as it navigates its clinical programs and partnerships.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.